Apomorphine - RP Scherer

Drug Profile

Apomorphine - RP Scherer

Latest Information Update: 14 Aug 2006

Price : $50

At a glance

  • Originator RP Scherer
  • Developer Orion; RP Scherer
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parkinson's disease

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 20 Oct 2003 Orion has terminated research of apomorphine and seeks to outlicense the agent
  • 15 Mar 2002 The fast-dissolving tablet formulation of apomorphine has received orphan drug status in Europe for the treatment of off-periods in patients with Parkinson's disease who are not responding to other oral medications
  • 15 Mar 2002 Phase-III clinical trials in Parkinson's disease in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top